AGIO — Agios Pharmaceuticals, Inc.
8 mentions in the last 24 hours · 0.04% of all mentions
Why people talked about AGIO (2026-10-30)
- Agios Pharmaceuticals received a new FDA goal date of February 1, 2027, for the supplemental NDA of mitapivat in sickle cell disease.
- The PDUFA date was moved from November 1 to February 1, 2027, following a request for additional REMS information.
- The company announced it is launch-ready and currently engaged in labeling discussions with the FDA.
| GDELT | 5 | news |
| Bluesky | 3 | community |